Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageNektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. We apply our deep understanding of immunology to identify and create innovative drug candidates and use our drug development expertise to advance these molecules through preclinical and clinical development.
In the company’s own words · 10-K filed Mar 13, 2026 · SEC EDGAR
Business segments
Q3 2025 · $11.8MThe company’s own SEC segment disclosure.
- Non Cash Royalty Revenue Related To Sale Of Future Royalties$11.5M97%
- License Collaboration And Other$300.0K3%
Nektar Therapeutics (NKTR) reported revenue of $11M in Q1 2026 (quarter ended March 31, 2026), up 3.8% from the same quarter a year earlier. That came with net loss of $45M. For the full year FY2025, revenue was $55M (−44% year on year) and net income −$164M. Its largest product in 2025-Q3 was Non Cash Royalty Revenue Related To Sale Of Future Royalties at $11M, 97% of the disclosed total, just ahead of License Collaboration And Other at 2.5%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.